| | DRUG: Haloperidol | |
Entry |
|
Name |
Haloperidol (JP18/USP/INN); Haldol (TN) |
Product |
|
Generic |
HALOPERIDOL (A-S Medication Solutions), HALOPERIDOL (Advagen Pharma), HALOPERIDOL (American Health Packaging), HALOPERIDOL (American Health Packaging), HALOPERIDOL (American Health Packaging), HALOPERIDOL (Amici Pharmaceuticals), HALOPERIDOL (Aurobindo Pharma Limited), HALOPERIDOL (Bryant Ranch Prepack), HALOPERIDOL (Bryant Ranch Prepack), HALOPERIDOL (Bryant Ranch Prepack), HALOPERIDOL (Bryant Ranch Prepack), HALOPERIDOL (Bryant Ranch Prepack), HALOPERIDOL (Bryant Ranch Prepack), HALOPERIDOL (Bryant Ranch Prepack), HALOPERIDOL (Bryant Ranch Prepack), HALOPERIDOL (Bryant Ranch Prepack), HALOPERIDOL (Bryant Ranch Prepack), HALOPERIDOL (Bryant Ranch Prepack), HALOPERIDOL (Bryant Ranch Prepack), HALOPERIDOL (Bryant Ranch Prepack), HALOPERIDOL (Burel Pharmaceuticals), HALOPERIDOL (Burel Pharmaceuticals), HALOPERIDOL (Burel Pharmaceuticals), HALOPERIDOL (Cardinal Health 107), HALOPERIDOL (Cardinal Health 107), HALOPERIDOL (Innogenix), HALOPERIDOL (Lifestar Pharma LLC), HALOPERIDOL (Major Pharmaceuticals), HALOPERIDOL (Major Pharmaceuticals), HALOPERIDOL (Marlex Pharmaceuticals), HALOPERIDOL (Method Pharmaceuticals), HALOPERIDOL (Mylan Institutional), HALOPERIDOL (Mylan Pharmaceuticals), HALOPERIDOL (NCS HealthCare of KY), HALOPERIDOL (Novadoz Pharmaceuticals LLC), HALOPERIDOL (Proficient Rx LP), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (REMEDYREPACK), HALOPERIDOL (Redpharm Drug), HALOPERIDOL (Redpharm Drug), HALOPERIDOL (Upsher-Smith Laboratories), HALOPERIDOL (Zydus Lifesciences Limited), HALOPERIDOL (Zydus Pharmaceuticals USA) |
Formula |
C21H23ClFNO2
|
Exact mass |
375.1401
|
Mol weight |
375.86
|
Structure |
|
Simcomp |
|
Class |
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
DG03200 Antipsychotic agent
DG01940 Butyrophenone derivative
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
Remark |
Therapeutic category: | 1179 |
Product (DG00885): | D00136<JP/US> D01898<JP/US> D08035<US> |
|
Efficacy |
Antipsychotic, Antidyskinetic, Neuroleptic, Dopamine D2 receptor antagonist |
Disease |
Tourette’s disorder [DS: H00862] |
Comment |
Butyrophenone derivative
|
Target |
|
Pathway |
hsa04080 | Neuroactive ligand-receptor interaction |
|
Metabolism |
Enzyme: CYP2D6 [HSA: 1565], CYP3A4 [HSA: 1576]
|
Interaction |
|
Structure map |
map07031 | Antipsychotics - butyrophenones |
map07213 | Dopamine receptor agonists/antagonists |
|
Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05A ANTIPSYCHOTICS
N05AD Butyrophenone derivatives
N05AD01 Haloperidol
D00136 Haloperidol (JP18/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Antipsychotics
1st Generation/Typical
Haloperidol
D00136 Haloperidol (JP18/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
117 Psychotropics
1179 Others
D00136 Haloperidol (JP18/USP/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
DG00885 Haloperidol
D00136 Haloperidol
DG03200 Antipsychotic agent
DG01940 Butyrophenone derivative
DG00885 Haloperidol
D00136 Haloperidol
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00885 Haloperidol
D00136 Haloperidol
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00885 Haloperidol
D00136 Haloperidol
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Dopamine
DRD2
D00136 Haloperidol (JP18/USP/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00136 Haloperidol
D00136 Haloperidol tablets
D00136 Haloperidol fine granules
D00136 Haloperidol injection
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00136
Prodrugs [br08324.html]
D00136
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
DG00885 Haloperidol
DG03200 Antipsychotic agent
DG01940 Butyrophenone derivative
DG00885 Haloperidol
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00885 Haloperidol
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00885 Haloperidol
Prodrugs [br08324.html]
DG00885
|
Other DBs |
|
KCF data |
ATOM 26
1 C1b C 19.7303 -17.5616
2 C1b C 20.9898 -16.8619
3 C1b C 22.2494 -17.5616
4 N1y N 23.4389 -16.8619
5 C1x C 23.4389 -15.4624
6 C1x C 24.6285 -17.5616
7 C1x C 24.6285 -14.7626
8 C1x C 25.8181 -16.8619
9 C1z C 25.8181 -15.4624
10 C8y C 27.0076 -14.7626
11 C8x C 27.0076 -13.4331
12 C8x C 28.2672 -15.4624
13 C8x C 28.2672 -12.7334
14 C8x C 29.4567 -14.7626
15 C8y C 29.4567 -13.4331
16 X Cl 30.6463 -12.7334
17 C5a C 18.5407 -16.8619
18 C8y C 17.3512 -17.5616
19 O5a O 18.5407 -15.3924
20 C8x C 17.3512 -18.9611
21 C8x C 16.0916 -19.6608
22 C8y C 14.8321 -18.9611
23 C8x C 14.8321 -17.5616
24 C8x C 16.0916 -16.8619
25 X F 13.6425 -19.6608
26 O1a O 27.0305 -16.1624
BOND 28
1 9 10 1
2 10 11 1
3 10 12 2
4 11 13 2
5 12 14 1
6 13 15 1
7 15 16 1
8 8 9 1
9 14 15 2
10 1 17 1
11 1 2 1
12 17 18 1
13 2 3 1
14 17 19 2
15 3 4 1
16 4 5 1
17 4 6 1
18 5 7 1
19 6 8 1
20 18 20 1
21 20 21 2
22 21 22 1
23 22 23 2
24 23 24 1
25 24 18 2
26 7 9 1
27 22 25 1
28 9 26 1
|
|
» Japanese version » Back
|
|